[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477340":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":28,"centralContacts":38,"locations":48,"responsibleParty":65,"collaborators":28,"id":67,"slug":28,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":28,"enrollmentInfo":75,"targetDuration":28,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":28,"overallStatus":51,"whyStopped":28,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Franciscus Gasthuis","OTHER",[8,13,18],{"label":9,"type":6,"description":10,"interventionNames":11},"Control group","multi-inhaler triple therapy (Qvar and Bevespi)",[12],"Drug: multi-inhaler triple therapy (Qvar + Bevespi)",{"label":14,"type":6,"description":15,"interventionNames":16},"Intervention group 1","single-inhaler triple therapy (Trimbow)",[17],"Drug: single-inhaler triple therapy (Trimbow)",{"label":19,"type":6,"description":20,"interventionNames":21},"Intervention group 2","single-inhaler triple therapy (Trimbow) + e-health applications",[17,22],"Device: E-health application: Curavista app & FindAir e-device",[24,29,34],{"type":25,"name":15,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.",[14,19],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"DEVICE","E-health application: Curavista app & FindAir e-device","Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir",[19],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"multi-inhaler triple therapy (Qvar + Bevespi)","Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.",[9],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":28,"email":43},"Liz Cuperus","CONTACT","+31108935567","l.cuperus@franciscus.nl",{"name":45,"role":41,"phone":46,"phoneExt":28,"email":47},"Hans in 't Veen","+31104616800","h.intveen@franciscus.nl",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Franciscus Gasthuis & Vlietland","RECRUITING","Rotterdam","South Holland","3045PM","Netherlands",{"type":57,"coordinates":58},"Point",[59,60],4.47917,51.9225,{"lat":60,"lon":59},[63],{"name":64,"role":41,"phone":42,"phoneExt":28,"email":43},"Liz Cuperus, Drs",{"type":66,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100477340",false,"NCT05495698","Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease","TRICOLON","Inclusion Criteria:\n\n* Clinical diagnosis of COPD for at least 1 year before the screening visit\n* Aged 40 years and older\n* An indication for triple therapy according to the treating physician (following the GOLD guideline 2021(2)). Could be step-up from dual therapy or currently receiving triple therapy (both MITT and SITT).\n* Owner of mobile device compatible with e-device app with access to internet (Android or iOS)\n* Willing to provide written informed consent\n* Current or ex-smoker\n\nExclusion Criteria:\n\n* Inability to comply with study procedures or with study treatment\n* Insufficiently skilled in the Dutch language to be able to read and understand the app. Help by third party (family members) is allowed\n* Asthma as the predominant disease according to the investigator's opinion, a past history of asthma is allowed\n* Use of e-health application for COPD in the past six months\n* Patients with any other therapy that could interfere with the study drugs (according to the investigator's opinion)\n* Use of nebulized bronchodilators, for example via pari boy\n* Pregnant or lactating women and all women physiologically capable of becoming pregnant unless they have highly effective contraceptive\n* Patients mentally or legally incapacitated, or patients accommodated in an establishment as a result of an official or judicial order\n* Patients without the capability to complete the questionnaires","ALL","40 Years",{"count":76,"type":77},300,"ESTIMATED","INTERVENTIONAL",[80],"NA","TRICOLON is an investigator initiated, prospective, interventional, open-label, randomized, real-world, multi-centre, 3-arms study in the Netherlands. The primary objective is to investigate in COPD patients if single-inhaler triple therapy (SITT) is superior to multi-inhaler triple therapy (MITT) in terms of adherence to inhaled corticosteroids (ICS) therapy and to investigate if SITT with e-health support is superior to MITT and SITT without e-health support.",[83,84],"Copd","Adherence, Medication","2025-08-20",{"date":87,"type":88},"2025-08-21","ACTUAL",{"date":90,"type":88},"2022-12-13",{"date":92,"type":77},"2026-12",{"name":5,"class":6},1]